Abeona Therapeutics (NASDAQ:ABEO) Director Leila Alland Sells 18,065 Shares of Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) Director Leila Alland sold 18,065 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $5.09, for a total transaction of $91,950.85. Following the sale, the director owned 173,614 shares in the company, valued at $883,695.26. The trade was a 9.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Abeona Therapeutics Stock Up 1.6%

Abeona Therapeutics stock opened at $5.17 on Tuesday. The firm has a 50 day simple moving average of $5.16 and a 200 day simple moving average of $5.59. The company has a current ratio of 9.74, a quick ratio of 9.53 and a debt-to-equity ratio of 0.06. Abeona Therapeutics Inc. has a 1-year low of $3.93 and a 1-year high of $7.54. The firm has a market capitalization of $280.16 million, a price-to-earnings ratio of 4.20 and a beta of 1.18.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.17. On average, analysts predict that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ABEO. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Abeona Therapeutics in a report on Monday, October 13th. Weiss Ratings restated a “sell (d+)” rating on shares of Abeona Therapeutics in a research report on Wednesday, January 21st. Finally, Wall Street Zen lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC purchased a new stake in Abeona Therapeutics in the fourth quarter worth about $10,540,000. PVG Asset Management Corp purchased a new stake in shares of Abeona Therapeutics during the 4th quarter valued at about $66,000. Aberdeen Group plc purchased a new stake in Abeona Therapeutics in the fourth quarter worth approximately $3,248,000. SG Americas Securities LLC purchased a new position in shares of Abeona Therapeutics in the 4th quarter worth $57,000. Finally, Sherbrooke Park Advisers LLC purchased a new position in Abeona Therapeutics in the third quarter worth about $64,000. 80.56% of the stock is owned by hedge funds and other institutional investors.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.